NCT05586061View on ClinicalTrials.gov

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

December 29, 2024

Study Completion Date

December 31, 2025

Conditions
HER2-positive Gastric Cancer
Interventions
DRUG

Disitamab vedotin

Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W

DRUG

Tislelizumab

Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W

DRUG

S1

S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.

Trial Locations (7)

250012

Central Hospital Affiliated to Shandong First Medical University, Jinan

Qilu Hospital of Shandong University, Jinan

Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan

264000

Yantai Yuhuangding Hospital, Yantai

266000

The Affiliated Hospital of Qingdao University, Qingdao

266011

Qingdao Municipal Hospital (Group), Qingdao

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER